keyword
https://read.qxmd.com/read/38455346/perspectives-on-surgical-treatment-for-thymic-epithelial-tumors-a-narrative-review
#21
REVIEW
Yusuke Nabe, Masaaki Inoue, Junichi Yoshida
BACKGROUND AND OBJECTIVE: Thymic epithelial tumors are relatively rare; thus, mostly retrospective studies and a few prospective randomized controlled trials have been conducted on the treatment and the biomarkers, with no standard therapy established. Indications for extended thymectomy, robot-assisted thoracic surgery, and multidisciplinary treatment are controversial. Here, we considered the prospects of surgical treatment and the possibility of immune checkpoint inhibitor (ICI) treatment for thymic epithelial tumors...
February 29, 2024: Gland Surgery
https://read.qxmd.com/read/38441340/aggregation-prone-peptides-from-within-a-non-self-protein-homoaggregate-are-preferred-for-mhc-association-historical-overview
#22
JOURNAL ARTICLE
Donald R Forsdyke
New technologies assist re-evaluation of hypotheses on generation of immune cell repertoires and distinctions of self from non-self. Findings include positive correlations between peptide propensities to aggregate and their binding to major histocompatibility complex (MHC) proteins. This recalls the hypothesis that foreign proteins may homoaggregate in host cytosols prior to releasing their peptides (p) to form pMHC complexes. Clues to this included aggregation-related phenomena associated with infections (rouleaux formation, pyrexia, certain brain diseases)...
October 2023: Scandinavian Journal of Immunology
https://read.qxmd.com/read/38426497/cancer-neoepitopes-viewed-through-negative-selection-and-peripheral-tolerance-a-new-path-to-cancer-vaccines
#23
REVIEW
Pramod K Srivastava
A proportion of somatic mutations in tumors create neoepitopes that can prime T cell responses that target the MHC I-neoepitope complexes on tumor cells, mediating tumor control or rejection. Despite the compelling centrality of neoepitopes to cancer immunity, we know remarkably little about what constitutes a neoepitope that can mediate tumor control in vivo and what distinguishes such a neoepitope from the vast majority of similar candidate neoepitopes that are inefficacious in vivo. Studies in mice as well as clinical trials have begun to reveal the unexpected paradoxes in this area...
March 1, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38421567/major-vascular-reconstructions-in-thoracic-oncological-surgery
#24
JOURNAL ARTICLE
Leonardo Duranti, Luca Tavecchio
The replacement of the superior vena cava and thoracic outlet vessels for thoracic malignancies often becomes necessary for radical oncological surgery. The pulmonary artery can be directly infiltrated by the tumor or affected by metastatic hilar lymph nodes. In some cases, it must be resected and reconstructed to achieve oncological radicality and/or avoid pneumonectomy. This study reflects a single-surgeon, retrospective experience spanning 6 years (2017-2023). We reviewed data from patients undergoing early anticoagulant therapy after superior vena cava or thoracic outlet vessels bypass and from patients undergoing early antiaggregation therapy following pulmonary artery reconstruction or resection...
February 29, 2024: Updates in Surgery
https://read.qxmd.com/read/38413246/artemis-a-multicenter-open-label-single-arm-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-first-line-carboplatin-paclitaxel-lenvatinib-pembrolizumab-combination-for-previously-untreated-advanced-or-recurrent-thymic-carcinomas
#25
JOURNAL ARTICLE
Yusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, Yoko Tsukita, Shuji Murakami, Yukio Hosomi, Yuichi Tambo, Yoshihito Kogure, Hiroshige Yoshioka, Motohiro Tamiya, Kiichiro Ninomiya, Eiji Iwama
BACKGROUND: Thymic carcinoma is a rare cancer with an aggressive clinical presentation and no organotypic symptoms. Despite using platinum-based chemotherapy as first-line treatment, the prognosis remains poor, necessitating a novel therapeutic strategy. METHODS: The artemis trial is a Phase II, single-arm, multicenter study designed to evaluate the efficacy and safety of carboplatin, paclitaxel, lenvatinib, and pembrolizumab as first-line chemotherapy for patients with advanced or recurrent thymic carcinoma...
February 8, 2024: Clinical Lung Cancer
https://read.qxmd.com/read/38366021/eortc-specta-arcagen-study-comprehensive-genomic-profiling-and-treatment-adaptation-of-rare-thoracic-cancers
#26
JOURNAL ARTICLE
Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Julio Oliveira, Laurent Greillier, Judith Raimbourg, Anne-Claire Toffart, Thierry Chatellier, Nicolas Cloarec, Ivana Sullivan, Birute Brasiuniene, Michael Duruisseaux, Kersti Oselin, Marie-Sophie Robert, Carolina Fernandes, Arnaud Poncin, Jean-Yves Blay, Benjamin Besse, Nicolas Girard
Arcagen (NCT02834884) is a European prospective study aiming at defining the molecular landscape of rare cancers for treatment guidance. We present data from the cohort of rare thoracic tumors. Patients with advanced pleural mesothelioma (PM) or thymic epithelial tumors (TET) underwent genomic profiling with large targeted assay [>300 genes, tumor mutational burden (TMB), microsatellite instability (MSI) status] on formalin-fixed paraffin-embedded (FFPE) or plasma samples. EORTC molecular tumor board (MTB) advised for biomarker-guided treatments...
February 16, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38347798/thymus-as-incontrovertible-target-of-future-immune-modulatory-therapeutics
#27
JOURNAL ARTICLE
Ghulam Jilany Khan, Abeeha Imtiaz, Wei Wang, Hong Duan, Hui Cao, Kefeng Zhai, Nongyue He
Thymus plays a crucial role in cellular immunity by acting as a warehouse for proliferating and differentiating lymphocytes. Thymic stromal cells educate T-cells to differentiate self from non-self antigens while nurse cells and thymoproteasome play a major role in the maturation and differentiation of T-cells. The thymic conditions dictate T-cells to cope with the risk of cancer development. A study was designed to demonstrate potential mechanisms behind the failure to eliminate tumors and impaired immune surveillance as well as the impact of delay in thymus regression on cancer and autoimmune disorders...
February 12, 2024: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/38338689/thymic-epithelial-cell-dependent-microenvironment-influences-proliferation-and-apoptosis-of-leukemic-cells
#28
JOURNAL ARTICLE
Sandesh Kumar Patel, Nadezda Zhdanovskaya, Ilaria Sergio, Antonella Cardinale, Marco Rosichini, Claudia Varricchio, Eleonora Pace, Carlo Capalbo, Franco Locatelli, Alberto Macone, Enrico Velardi, Rocco Palermo, Maria Pia Felli
T-cell acute lymphoblastic leukemia (T-ALL) is a hematological cancer characterized by the infiltration of immature T-cells in the bone marrow. Aberrant NOTCH signaling in T-ALL is mainly triggered by activating mutations of NOTCH1 and overexpression of NOTCH3, and rarely is it linked to NOTCH3-activating mutations. Besides the known critical role of NOTCH, the nature of intrathymic microenvironment-dependent mechanisms able to render immature thymocytes, presumably pre-leukemic cells, capable of escaping thymus retention and infiltrating the bone marrow is still unclear...
January 24, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38328473/a-phase-1-2-study-to-evaluate-the-safety-and-activity-of-nivolumab-in-combination-with-vorolanib-a-vascular-endothelial-growth-factor-tyrosine-kinase-inhibitor-in-patients-with-refractory-thoracic-tumors
#29
JOURNAL ARTICLE
Kathryn E Beckermann, Christine M Bestvina, Badi El Osta, Rachel E Sanborn, Hossein Borghaei, Philip Edward Lammers, Giovanni Selvaggi, Jennifer G Whisenant, Ellen Heimann-Nichols, Lynne Berry, Chih-Yuan Hsu, Yu Shyr, Leora Horn, Heather Wakelee
INTRODUCTION: Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested the safety and efficacy of vorolanib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and c-KIT, in combination with programmed cell death protein 1 blockade using nivolumab for refractory thoracic malignancies. METHODS: This single-arm multicenter study enrolled patients with extensive-stage SCLC, thymic carcinoma, and NSCLC, either naive or had progressed on previous chemotherapy or immune checkpoint inhibitors (either primary or acquired resistance)...
February 2024: JTO clinical and research reports
https://read.qxmd.com/read/38328457/microscopic-thymoma-with-a-thymic-cyst-that-enlarged-over-a-2-year-period
#30
Hiroaki Komatsu, Nao Furukawa, Hirotaka Kinoshita, Kazunori Okabe
An 81-year-old woman was referred to our hospital because of right lung cancer. She underwent right upper lobectomy. Pathological examination revealed stage 1A adenocarcinoma. Four months postoperatively, chest computed tomography showed a small nodule with a diameter of 6 mm at the anterior mediastinum. After 2 years, the nodule had increased to 13 mm. To confirm the diagnosis and treat the mediastinal tumor, we resected the tumor and surrounding thymic tissue by a left robotic thoracic approach, considering the adhesion in the right thoracic cavity after right pulmonary resection...
February 2024: Journal of Surgical Case Reports
https://read.qxmd.com/read/38323230/stage-iii-iv-thymic-squamous-cell-carcinoma-in-complete-pathological-remission-achieved-with-thymic-cancer-resection-after-immunotherapy-combined-with-chemotherapeutic-conversion-therapy-a-report-of-two-cases-from-real-world-data
#31
Dong Li, Fabrizio Minervini, Georgina Planas, Katsuhiro Okuda, Naoki Ozeki, Yingbo Zou
BACKGROUND: Thymic carcinoma, a rare malignancy in the mediastinum, currently lacks standardized treatment options. Although surgery remains a crucial component among traditional therapeutic approaches, the potential benefits of radiotherapy and chemotherapy remain controversial. Nevertheless, a substantial number of patients are diagnosed with advanced tumor growth, posing challenges for achieving complete resection through surgical intervention and resulting in a poor prognosis. In light of the promising antitumor effects demonstrated by immunotherapy in various prevalent cancers, certain studies have shown favorable efficacy in advanced or recurrent thymic cancer cases...
January 29, 2024: Gland Surgery
https://read.qxmd.com/read/38322188/perioperative-management-and-postoperative-outcomes-of-locally-advanced-thymic-epithelial-tumors-a-narrative-review
#32
REVIEW
Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka
BACKGROUND AND OBJECTIVE: Thymic epithelial tumors (TETs) are frequently diagnosed at an advanced stage, highlighting the importance of understanding the treatment strategies for these cases. Surgical intervention after chemotherapy or chemoradiotherapy presents specific challenges and underscores the crucial role of perioperative management. This study aimed to explore the perioperative management and postoperative outcomes in patients with locally advanced TETs. METHODS: Relevant studies published between 2000 and 2022 were identified through PubMed searches using a combination of the following terms: "Locally advanced TETs", "Thymoma", "Thymic cancer", "Surgery", "Induction therapy", and "Postoperative outcomes"...
2024: Mediastinum
https://read.qxmd.com/read/38306885/international-reproducibility-study-of-thymic-epithelial-tumors-staging-pt-stage-is-an-issue-proposals-for-improvement-a-rythmic-itmig-study
#33
JOURNAL ARTICLE
Thierry J Molina, Anja C Roden, Malgorzata Szolkowska, Shigeki Shimizu, Andre L Moreira, Lara Chalabreysse, Benjamin Besse, Vincent de Montpréville, Edith M Marom, Frank Detterbeck, Nicolas Girard, Andrew G Nicholson, Alexander Marx
INTRODUCTION: Pathologists are staging thymic epithelial tumors (TET) according to the 8th UICC/AJCC TNM system. Within the French RYTHMIC network, dedicated to TET, agreement on pathologic tumor stage (pT) among the pathology panelists was difficult. The aim of our study was to determine the interobserver reproducibility of pT at an international level, to explore the source of discrepancies and potential interventions to address these. METHODS: An international panel of pathologists was recruited through the International Thymic Malignancy Interest Group (ITMIG)...
January 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38303274/-a-case-of-small-thymic-carcinoma-with-pleural-dissemination-preoperatively-suspected-as-pulmonary-metastasis-from-rectal-cancer
#34
JOURNAL ARTICLE
Ryosuke Matsuda, Naozumi Higaki, Fumiaki Abe, Shinichi Adachi, Yujiro Fujie, Shigeyuki Ueshima, Hirohito Hayashida, Tadashi Ohnishi, Masahiro Ayata
A case was 73-year-old man, who had history of laparoscopic high anterior resection surgery for rectal cancer, followed by adjuvant chemotherapy 2 years ago. Preoperative diagnosis was anterior mediastinal tumor, with multiple intrapulmonary nodules noted, though no increasing tendency. During adjuvant chemotherapy for colorectal cancer, the anterior mediastinal tumor showed some shrinkage, while that and 3 intrapulmonary nodules slowly increased in size after completion, thus rectal cancer pulmonary and mediastinal metastasis were suspected...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38276989/immune-modulation-with-rankl-blockade-through-denosumab-treatment-in-patients-with-cancer
#35
JOURNAL ARTICLE
Hewitt Chang, Jaqueline Marquez Garcia, Brandon K Chen, Daniel M Kim, Michael L Cheng, Eric V Liu, Hai Yang, Li Zhang, Meenal Sinha, Alexander Cheung, Serena S Kwek, Eric D Chow, Mark Bridge, Rahul R Aggarwal, Terence W Friedlander, Eric J Small, Mark Anderson, Lawrence Fong
Denosumab is a fully human monoclonal antibody that binds receptor activator of nuclear factor-κB ligand (RANKL). It is routinely administered to cancer patients to reduce the incidence of new bone metastasis. RANK-RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells (mTECs). Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells...
January 26, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38276116/tnm-staging-system-in-thymoma-a-critical-appraisal
#36
REVIEW
Marcello Carlo Ambrogi, Vittorio Aprile, Alessandra Lenzini, Diana Bacchin, Maria Giovanna Mastromarino, Stylianos Korasidis, Marco Lucchi
Thymomas are rare tumors of the anterior mediastinum with peculiar clinical and pathological features. They have been deeply analyzed by pioneer authors, who strictly linked their name to the main pathological and staging classifications. Before the latest edition of the WHO classification of thymic epithelial tumors, the history of thymoma pathological classification inherited the name of the pathologists who systematically addressed the issue, from Levine-Rosai to Muller-Hermelink. Similarly, the thymoma staging system is intimately related to the name of two surgeons, Masaoka and Koga, who historically dealt with this disease...
January 21, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38254905/what-have-we-learned-from-molecularly-informed-clinical-trials-on-thymomas-and-thymic-carcinomas-current-status-and-future-directions
#37
REVIEW
Rohan Maniar, Patrick J Loehrer
Thymic epithelial tumors (TETs), which include thymomas and thymic carcinomas, are a rare, heterogeneous group of malignancies that originate from the thymus gland. As an important organ of immune cell development, thymic tumors, particularly thymomas, are often associated with paraneoplastic autoimmune disorders. The advances in targeted therapies for both solid and hematologic malignancies have resulted in improved patient outcomes, including better and more durable efficacy and improved toxicity. Targeted therapies have also been investigated in the treatment of TETs, though the results have largely been modest...
January 18, 2024: Cancers
https://read.qxmd.com/read/38254894/national-multicenter-study-on-the-comparison-of-robotic-and-open-thymectomy-for-thymic-neoplasms-in-myasthenic-patients-surgical-neurological-and-oncological-outcomes
#38
JOURNAL ARTICLE
Elisa Sicolo, Carmelina Cristina Zirafa, Gaetano Romano, Jury Brandolini, Angela De Palma, Stefano Bongiolatti, Filippo Tommaso Gallina, Sara Ricciardi, Michelangelo Maestri, Melania Guida, Riccardo Morganti, Graziana Carleo, Giovanni Mugnaini, Riccardo Tajè, Fabrizia Calabró, Alessandra Lenzini, Federico Davini, Giuseppe Cardillo, Francesco Facciolo, Luca Voltolini, Giuseppe Marulli, Piergiorgio Solli, Franca Melfi
Thymectomy is the gold standard in the treatment of thymic neoplasm and plays a key role in the therapeutic path of myasthenia gravis. For years, sternotomy has been the traditional approach for removing anterior mediastinal lesions, although the robotic thymectomy is now widely performed. The literature is still lacking in papers comparing the two approaches and evaluating long-term oncological and neurological outcomes. This study aims to analyze the postoperative results of open and robotic thymectomy for thymic neoplasms in myasthenic patients...
January 18, 2024: Cancers
https://read.qxmd.com/read/38254821/aberrant-dna-methylation-of-nptx2-as-an-indicator-of-malignant-behavior-in-thymic-epithelial-tumors
#39
JOURNAL ARTICLE
Kazuya Kondo, Kyoka Muguruma, Shiho Soejima, Chikako Takai, Koichiro Kenzaki, Naoya Kawakita, Hiroaki Toba, Hiromitsu Takizawa
Thymic epithelial tumors (TET) consist of thymomas, thymic carcinoma (TC), and neuroendocrine tumors of the thymus (NECTT). Genetic and epigenetic alterations in TET have been the focus of recent research. In the present study, genome-wide screening was performed on aberrantly methylated CpG islands in TET, and this identified neuronal pentraxin 2 (NTPX2) as a significantly hypermethylated CpG island in TC relative to thymomas. NPTX2 is released from pre-synaptic cells in response to neuronal activity/seizure, and plays a role in host immunity and acute inflammation...
January 11, 2024: Cancers
https://read.qxmd.com/read/38242729/trop-2-expression-and-its-impact-on-survival-in-thymic-epithelial-tumors-brief-report
#40
Fatemeh Ardeshir-Larijani, Rohan Maniar, Subir Goyal, Patrick J Loehrer, Tieying Hou, Victoria DeBrock, Hector Mesa
No abstract text is available yet for this article.
January 2, 2024: Clinical Lung Cancer
keyword
keyword
50102
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.